• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate.

作者信息

Bachy Emmanuel, Bernaud Janine, Roy Pascal, Rigal Dominique, Nicolini Franck E

出版信息

Br J Haematol. 2011 Apr;153(1):139-43. doi: 10.1111/j.1365-2141.2010.08453.x. Epub 2011 Jan 31.

DOI:10.1111/j.1365-2141.2010.08453.x
PMID:21275952
Abstract
摘要

相似文献

1
Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate.
Br J Haematol. 2011 Apr;153(1):139-43. doi: 10.1111/j.1365-2141.2010.08453.x. Epub 2011 Jan 31.
2
Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.甲磺酸伊马替尼治疗慢性期慢性髓性白血病的持续优异长期疗效和细胞遗传学反应：来自发展中国家的报告。
Jpn J Clin Oncol. 2010 Jun;40(6):549-55. doi: 10.1093/jjco/hyq012. Epub 2010 Feb 26.
3
Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner.伊马替尼以剂量依赖的方式损害CD4+CD25+调节性T细胞的增殖和功能。
Int J Oncol. 2007 Nov;31(5):1133-9.
4
[Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].甲磺酸伊马替尼（格列卫）治疗慢性期慢性髓性白血病
Vnitr Lek. 2004 Jan;50(1):21-3, 26-9.
5
[Chronic myeloid leukemia and imatinib mesylate therapy].
Vnitr Lek. 2004 Jan;50(1):10-2.
6
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.使用甲磺酸伊马替尼通用制剂对慢性期慢性髓性白血病患者进行一线治疗。
Br J Haematol. 2014 Oct;167(1):139-41. doi: 10.1111/bjh.12937. Epub 2014 May 10.
7
Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib.未接受α干扰素或伊马替尼治疗的慢性期慢性髓性白血病患者的正常固有Th1/Th2平衡
Haematologica. 2003 Jul;88(7):754-61.
8
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.伊马替尼治疗1年内获得完全细胞遗传学缓解的费城染色体阳性慢性期慢性髓性白血病患者与治疗12个月后获得该缓解的患者之间的比较。
J Clin Oncol. 2006 Jan 20;24(3):454-9. doi: 10.1200/JCO.2005.03.2011.
9
Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.甲磺酸伊马替尼治疗儿童费城染色体阳性白血病
Cancer. 2003 Dec 15;98(12):2643-50. doi: 10.1002/cncr.11895.
10
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.伊马替尼与干扰素α加小剂量阿糖胞苷治疗新诊断慢性期慢性髓性白血病患者的生活质量：IRIS研究结果
J Clin Oncol. 2003 Jun 1;21(11):2138-46. doi: 10.1200/JCO.2003.12.154.

引用本文的文献

1
Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib.通用型伊马替尼治疗的慢性髓性白血病患者中调节性T细胞和PD-1 + CD8 T细胞的预后意义
Indian J Hematol Blood Transfus. 2024 Oct;40(4):580-587. doi: 10.1007/s12288-024-01843-6. Epub 2024 Aug 20.
2
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.达沙替尼通过抑制 T 细胞受体和 STAT5 信号通路来发挥其在慢性期慢性髓性白血病中的免疫调节作用。
Haematologica. 2023 Jun 1;108(6):1555-1566. doi: 10.3324/haematol.2022.282005.
3
Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission.
酪氨酸激酶抑制剂在慢性髓性白血病患者中的停药：与无治疗缓解相关的生物学因素综述。
Curr Oncol Rep. 2022 Apr;24(4):415-426. doi: 10.1007/s11912-022-01228-w. Epub 2022 Feb 10.
4
Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells.利用针对慢性髓性白血病干细胞的免疫反应的新型治疗策略。
Cancers (Basel). 2021 Oct 29;13(21):5435. doi: 10.3390/cancers13215435.
5
Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells.表达 Tnfrsf4 的调节性 T 细胞促进慢性髓性白血病干细胞的免疫逃逸。
JCI Insight. 2021 Dec 8;6(23):e151797. doi: 10.1172/jci.insight.151797.
6
Treatment-Free Remission-A New Aim in the Treatment of Chronic Myeloid Leukemia.无治疗缓解——慢性髓性白血病治疗的新目标。
J Pers Med. 2021 Jul 22;11(8):697. doi: 10.3390/jpm11080697.
7
Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.慢性髓性白血病患者酪氨酸激酶抑制剂成功停药的预测指标
World J Clin Oncol. 2020 Dec 24;11(12):996-1007. doi: 10.5306/wjco.v11.i12.996.
8
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.可药物化的生化途径和潜在的治疗选择，以靶向白血病干细胞并消除慢性髓性白血病中的残留疾病。
Int J Mol Sci. 2019 Nov 10;20(22):5616. doi: 10.3390/ijms20225616.
9
Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies.调节性 T 细胞及其在血液系统恶性肿瘤中的预后相关性。
J Immunol Res. 2017;2017:1832968. doi: 10.1155/2017/1832968. Epub 2017 Dec 21.
10
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.单核细胞来源的髓样抑制细胞作为接受达沙替尼治疗的慢性髓性白血病患者的预后因素。
J Cell Mol Med. 2018 Feb;22(2):1070-1080. doi: 10.1111/jcmm.13326. Epub 2017 Dec 8.